/
Oncology
B-Cell Non Hodgkin Lymphoma
18
Pipeline Programs↗
14
Active Trials↗
13
Companies Involved↗
B-cell Non Hodgkin Lymphoma is an emerging landscape with 18 programs across 13 companies. The most active players are AstraZeneca, Iksuda Therapeutics Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 17
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
16programs
Small molecule956%
Monoclonal antibody425%
Antibody–drug conjugate213%
Cell therapy16%
Modality classified for 89% of 18 pipeline programs.
Analysis
Trial Status
15
clinical trials
Active, not recruiting8 · 53%
Recruiting5 · 33%
Completed1 · 7%
Not yet recruiting1 · 7%
Clinical Trials
Trial Activity
15 trials
A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
Active, not recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 1·NCT06251180·112 enrolled
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06464185·53 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)